



2 October 2015
EMA/MB/169330/2015 V.3 Adopted
Management Board meeting of 2 October 2015

Agenda of the 89th meeting of the Management Board

Held on 2 October 2015, Room 2A (08:00 – 15:00)

Chair: Sir Kent Woods

Item	Preliminary draft agenda	Action / Reference
1.	Draft agenda	For adoption, EMA/MB/169330/2015 *
2.	Declaration of conflicts of interest related to current agenda	Oral report
3.	Minutes of the 88th meeting, held on 11 June 2015 adopted via written procedure on 24 July 2015	For information, EMA/MB/313120/2015*
A	Points for automatic adoption/endorsement	
B	Points for discussion	
B.1	Highlights of the Deputy Executive Director	Oral report
B.2	Report from the European Commission	Oral report
B.3	EMA mid-year report 2015 from the Deputy Executive Director (January - June 2015)	For information, EMA/MB/606869/2015; EMA/506004/2015*
B.4	Amending Budget 01-2015	For adoption, EMA/MB/50215/2015*
B.5	Amended guiding principles for a revision of the EMA conflicts of interests policy for the Management Board	For information, EMA/MB/616238/2015; For discussion, EMA/MB/553180/2015; EMA/615976/2015
B.6	Implementation of EMA policy on publication of clinical data – Status report	For information, EMA/MB/614812/2015*; EMA/614336/2015*
B.7	Review of Internal Control Standards and Underlying Framework	For information, EMA/MB/603324/2015; MA/MB/555181/2010 For adoption, EMA/MB/602884/2015*



B.8	Draft EMA Framework for interaction with Industry Stakeholders	For information, EMA/MB/603766/2015; SANTE.DDG02.03/JV/sc (2015) 4031402; For adoption, EMA/591272/2014*
B.9	Update on the development of CT Portal and Database	Oral report
B.10	Transparency rules for Clinical Trial Regulation	For information, EMA/MB/585266/2015 For endorsement, EMA/228383/2015*
B.11	Report from HMPC Chair	Oral report
B.12	Sixth interim report of the Steering Group to the Management Board	For information, EMA/MB/615242/2015
B.13	Joint annual report on the interaction with patients', consumers' and healthcare professionals' organisations (2014)	For information, EMA/MB/604206/2015 For endorsement, EMA/9496/2015*
B.14	Enhanced early dialogue to foster development and facilitate accelerated assessment	Oral report
C	Points for information only**	
C.1	Report on EU Telematics	For information, EMA/MB/603994/2015; EMA/MB/470927/2015
C.2	Feedback from the Heads of Medicines Agencies	For information
C.3	Outcome of written procedures finalised during the period from 9 May 2015 to 1 September 2015	For information, EMA/MB/480836/2015*
C.4	Results of ex ante and ex post evaluations of programmes and projects Art 29 (5) of the Financial Regulation	For information, EMA/MB/567811/2015; EMA/MB/566902/2015
C.5	Summary of the transfers of appropriation 2015	For information, EMA/MB/567233/2015*
C.6	Confidentiality (administrative) arrangements concluded with Swissmedic and WHO	For information, EMA/MB/604859/2015; 150709; 150710; Ref. Ares(2015)3292975 - 06/08/2015; EXT/605974/2015; EXT/605975/2015;
C.7	Veterinary EudraVigilance status report	For information, EMA/MB/606173/2015; EMA/13787/2009*

* Final documents marked with a star * are intended for publication on the external web site

** Documents in Additional documents for information section are not indented for discussion unless specifically requested